Ernexa Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

ERNA$2.01-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

ERNEXA THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the three and nine months ended September 30, 2026 and 2025 (unaudited)

(In thousands)

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at July 1, 2026	156	$1	1,170	$6	$258,352	$(255,159)	$3,200
Issuance of common stock under ATM, net	-	-	475	2	3,713	-	3,715
Stock-based compensation	-	-	-	-	377	-	377
Net loss	-	-	-	-	-	(2,941)	(2,941)
Balances at September 30, 2026	156	$1	1,645	$8	$262,442	$(258,100)	$4,351

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2026	156	$1	314	$2	$248,034	$(245,636)	$2,401
Issuance of common stock, prefunded warrants and warrants in connection with public offering, net	-	-	769	4	9,537	-	9,541
Issuance of common stock from the exercise of prefunded warrants, net	-	-	80	-	20	-	20
Issuance of common stock to consultant for services	-	-	5	-	120	-	120
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	1	-	8	(8)	-
Issuance of common stock under ATM, net	-	-	476	2	3,719	-	3,721
Stock-based compensation	-	-	-	-	1,004	-	1,004
Net loss	-	-	-	-	-	(12,456)	(12,456)
Balances at September 30, 2026	156	$1	1,645	$8	$262,442	$(258,100)	$4,351

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at July 1, 2025	156	$1	300	$2	$247,326	$(242,886)	$4,443
Issuance of common stock in connection with exercise of prefunded warrants	-	-	13	-	26	-	26
Issuance of common stock to consultant for services	-	-	1	-	48	-	48
Stock-based compensation	-	-	-	-	293	-	293
Net loss	-	-	-	-	-	(1,240)	(1,240)
Balances at September 30, 2025	156	$1	314	$2	$247,693	$(244,126)	$3,570

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2025	156	$1	137	$1	$233,235	$(231,536)	$1,701
Issuance of common stock to Series A preferred stockholders in lieu of cash dividends	-	-	-	-	8	(8)	-
Issuance of common stock in connection with exercise of prefunded warrants	-	-	16	-	30	-	30
Issuance of common stock to consultant for services	-	-	2	-	141	-	141
Issuance of common stock in connection with settlement	-	-	1	-	69	-	69
Issuance of common stock and prefunded warrants in connection with private placement	-	-	158	1	13,047	-	13,048
Stock-based compensation	-	-	-	-	1,163	-	1,163
Net loss	-	-	-	-	-	(12,582)	(12,582)
Balances at September 30, 2025	156	$1	314	$2	$247,693	$(244,126)	$3,570

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.